2023年6月15日

美國國防部高級研究計劃局,西門子,U。年代一個RMY, Georgia Tech Research Institute and Paragraf - through recently acquired Cardea Bio, now Paragraf San Diego - have presented novel multiomics capabilities, by detection of both protein and RNA biosignals simultaneously on a single graphene-based biosensor. It was stated that this achievement marks the first public demonstration of this novel methodology for multiomics and that the paper is the first in the world demonstrating the capability to detect both protein and RNA biosignals in a COVID-19 based experiment where both the COVID wild type as well as the Omicron variant were successfully detected. Dr. Kiana Aran, Chief Innovation Officer at Paragraf San Diego, said: "Having a single technology platform that can detect both protein and DNA/RNA biosignal analytes at the same time on a small-scale detection device, is a major technological advancement. While it initially will impact when and where we can detect viral infections, with time it will also work for other types of diseases. This will enable new, better, and way faster diagnoses for any types of diseases or biothreats." Dr. Simon Thomas, CEO at Paragraf, added: "This project was initiated during the COVID-19 pandemic to foster technologies that could be rapidly deployed to detect new diseases, envisioning a flexible multiomics point of care detection platform for any future pandemics. Together with partners, our Paragraf team in San Diego successfully completed this initiative accomplishing the goal set out by DARPA. More importantly, this novel breakthrough combined with Paragraf's unique ability to mass produce graphene-based electronics with standard semiconductor processes, marks the beginning of a new direction for what's possible in point of care testing." "Up to this point, PCR has been the mainstay of DNA/RNA detection done at any scale. However, this technology has not been available as a convenient or rapid point of care resource. Along with that, antibody/antigen lateral flow tests are the go-to tools for rapid point of care protein detection, but on their own cannot provide the lab-level accuracy of PCR. The outcome of this multiomics project represents the first generation of a novel multiomics platform that – with comparable accuracy and specificity – can drive a new level of point of care disease detection. You can think of this as offering lab-level accuracy as well as the convenience and ease-of-use of lateral flow tests", concludes Dr. Tom Wilson, Chief Commercial Officer at Paragraf. Paragraf's novel multiomics methodology is based on their BPU (Biosignal Processing Unit) platform and is currently available for Research Use Only. Paragraf is actively looking for early access partners to develop new applications on the platform. Source: